Agilent Technologies Introduces Verified Dissolution Components for Pharmaceutical Market
News May 15, 2013
Designed to ensure compliance with mechanical qualification guidelines, these components will be available June 1 and offer verification that they conform to exact specifications.
Dissolution is a technique used in the pharmaceutical industry to determine the rate at which pure active pharmaceutical ingredients dissolve. To meet precise tolerances, the new molded vessels are vacuum-formed around a set of Agilent’s mandrils, which eliminates the warps and flaws of traditional hand-blown manufacturing.
“To better support the qualification needs of our customers, it was critical for Agilent to offer improved options for component verification and traceability,” said Allan Little, director of marketing for dissolution systems at Agilent. “Not only do we offer these new vessels and shafts, but Agilent is leading the effort to educate pharmaceutical analysts on the importance of compliance with the developing qualification guidelines.”
The verified paddle and basket shafts are being introduced to meet a growing demand for verified components. Made with updated manufacturing processes, these shafts are measured to exact specifications and certified for traceability with an individual certificate of conformance.
Qualification of dissolution apparatus in pharmaceutical laboratories involves performance verification testing, enhanced mechanical qualification, or a combination of the two procedures. With evolving guidance on qualification best practices, the adoption of verified components assists with long-term traceability and offers assurance that components meet tolerances set by the United States Pharmacopeia.
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Cancer Cells Force Normal Cells to Act Like Viruses, Helping Tumors SpreadNews
Researchers reveal how cancer cells force normal cells to act like viruses – allowing tumors to grow, resist treatment, and spread.READ MORE
Edith Heard Unanimously Selected as Next Director General of EMBLNews
At its 53rd meeting yesterday, EMBL Council selected Edith Heard as the organization’s fifth Director General. Heard’s mandate is scheduled to begin 1 January 2019.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018